Publications by authors named "Alberto Morell"

Article Synopsis
  • - The study aimed to assess the quality of life in patients with common immune-mediated inflammatory diseases in Spain (like IBD, psoriasis, RA, etc.) and identify factors affecting their quality of life.
  • - Conducted in four hospitals in Madrid, this observational study analyzed 578 adult patients using various questionnaires to measure aspects like mobility, pain, and anxiety.
  • - The results indicated that patients with psoriasis and inflammatory bowel disease had better quality of life scores compared to those with psoriatic arthritis and rheumatoid arthritis, and factors such as gender, disease severity, age, and treatment persistence significantly impacted quality of life.
View Article and Find Full Text PDF

Cystic fibrosis (CF) is a genetic and multisystemic disease that requires a high therapeutic demand for its control. The aim of this study was to assess therapeutic adherence (TA) to different treatments to study possible clinical consequences and clinical factors influencing adherence. This is an ambispective observational study of 57 patients aged over 18 years with a diagnosis of CF.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluates patient satisfaction with healthcare among individuals suffering from prevalent immune-mediated inflammatory diseases (IMIDs) in Spain, specifically focusing on conditions like inflammatory bowel disease (IBD), psoriasis (Ps), psoriatic arthritis (PsA), rheumatoid arthritis (RA), and spondyloarthropathies (SpAs).
  • Conducted in four hospitals within the Community of Madrid, the research involved 578 adult patients using questionnaires to assess their experiences and health-related quality of life.
  • Results indicated a general satisfaction score of 6.6 out of 10, with RA patients reporting the lowest satisfaction, while factors like productive interactions and patient self-management received higher scores in terms of healthcare experience.
View Article and Find Full Text PDF

We herein describe an inter-specialists unit for the monitoring and management of biological therapies and analyze the utilization of biological agents across specialties and diseases. Protocols and therapeutic objectives, as well as outcomes and protocol deviations, are shared and discussed periodically between specialists. All patients treated at one centre with any biological treatment from January 2000 by rheumatology, gastroenterology, dermatology, or neurology, regardless diagnosis, are identified by Clinical Pharmacy and included in an ongoing database that detects use and outcome.

View Article and Find Full Text PDF